



UCB S.A. 60 Allée de la Recherche, B-1070 Brussels (Belgium)

Press Release

UCB APPOINTS DETLEF THIELGEN AS CHIEF FINANCIAL OFFICER

Brussels (Belgium), 16 July 2007 at 7:00 AM (CET) - UCB announces that Detlef Thielgen (46) is appointed Chief Financial Officer (CFO) of UCB with effect from 1 September 2007. As previously announced, Luc Missorten will continue as CFO until that date to ensure an orderly handover and then leave to pursue new opportunities.

Roch Doliveux, Chief Executive Officer of UCB said, "I am delighted with the appointment of Detlef as new CFO. His in-depth knowledge of Schwarz Pharma and extensive experience in the pharma industry will make a major contribution as we build UCB into the next generation biopharma leader."

On 1 January 2007, Detlef Thielgen was appointed Chief Executive Officer (CEO) of Schwarz Pharma AG and has served as Schwarz Pharma's CFO since 2002. He was appointed to the Executive Committee of UCB in January 2007.

Detlef joined Schwarz Pharma in 1989 and in 1994 was appointed Head of Group Controlling. His responsibilities included treasury, taxes, consolidation and operational and strategic controlling. Between 1995 and 1999 he was CFO of Schwarz Pharma USA and then, until 2002, was General Manager of Schwarz Pharma's worldwide manufacturing and supply chain operations. Effective 1 February 2002 he was appointed as deputy Executive Board member and effective 1 July 2002 as Member of the Executive Board of Schwarz Pharma and CFO.

About UCB

Headquartered in Brussels (Belgium), UCB (www.ucb-group.com) is a leading global biopharmaceutical company dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology. UCB focuses on securing a leading position in severe disease categories. Employing more than 8,400 people in over 40 countries, UCB achieved revenue of 2.5 billion euro in 2006. UCB is listed on the Euronext Brussels Exchange and owns 87.6% of Schwarz Pharma.

For further enquiries, please contactInvestor Relations

Antje Witte

Phone + 49 2173 481 866

+ 32 2 559 9346

Mareike Mohr

Phone +32 2 559 9264

Media Relations

Jean-Christophe Donck

Phone +32 2 559 9346